Nivolumab plus ipilimumab, with or without enzalutamide, in AR‐V7‐expressing metastatic castration‐resistant prostate cancer: A phase‐2 nonrandomized clinical trial-Reference-Cited by-同舟云学术

Nivolumab plus ipilimumab, with or without enzalutamide, in AR‐V7‐expressing metastatic castration‐resistant prostate cancer: A phase‐2 nonrandomized clinical trial

Published:2021-02-26 Issue:6 Volume:81 Page:326-338
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Shenderov Eugene¹²^ORCID,Boudadi Karim¹,Fu Wei³,Wang Hao³^ORCID,Sullivan Rana¹,Jordan Alice¹,Dowling Donna¹,Harb Rana¹,Schonhoft Joseph⁴,Jendrisak Adam⁴,Carducci Michael A.¹,Eisenberger Mario A.¹,Eshleman James R.⁵,Luo Jun⁶,Drake Charles G.⁷,Pardoll Drew M.¹²,Antonarakis Emmanuel S.¹²^ORCID

Affiliation:

1. Department of Oncology Johns Hopkins University School of Medicine Baltimore Maryland USA

2. The Bloomberg‐Kimmel Institute for Cancer Immunotherapy Johns Hopkins University School of Medicine Baltimore Maryland USA

3. Department of Oncology Biostatistics and Bioinformatics Johns Hopkins University School of Medicine Baltimore Maryland USA

4. Epic Sciences Inc. San Diego California USA

5. Department of Pathology Johns Hopkins University School of Medicine Baltimore Maryland USA

6. Department of Urology Johns Hopkins University School of Medicine Baltimore Maryland USA

7. Department of Hematology/Oncology Columbia University Medical Center New York New York USA

Funder

Prostate Cancer Foundation

Bristol-Myers Squibb

National Institutes of Health

U.S. Department of Defense

Publisher

Wiley

Subject

Urology,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.24110

Reference51 articles.

1. Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer

2. AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

3. Alternative splicing in prostate cancer

4. Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study

5. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Peripheral blood cytokines and outcomes with immune checkpoint blockade: a systematic review and meta-analysis;Immunotherapy;2024-08-19

2. Complete remission following pembrolizumab in a man with mCRPC with both microsatellite instability and BRCA2 mutation;The Oncologist;2024-06-26

3. Clinical Applications of the Gut Microbiome in Genitourinary Cancers;American Society of Clinical Oncology Educational Book;2024-06

4. The role of immunotherapy in urological cancers;Archivio Italiano di Urologia e Andrologia;2024-05-30

5. Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial;Clinical Cancer Research;2024-05-24